Comparison of statistically derived ASAS improvement criteria for ankylosing spondylitis with clinically relevant improvement according to an expert panel

Annals of the Rheumatic Diseases

Volumn 62, Issue 3, 2003, Pages 215-221

  Van Tubergen, A ^a   Van Der Heijde, D ^a,b   Anderson, J ^c   Landewe R ^a   Dougados, M ^d   Braun, J ^e   Bellamy, N ^f   Udrea, G ^g   Van Der Linden, Sj ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HASSELT UNIVERSITY   (Belgium)

^c BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^d Hospital Cochin ^*  (France)

^e RHEUMAZENTRUM RUHRGEBIET   (Germany)

^f UNIVERSITY OF QUEENSLAND   (Australia)

^g CANTACUZINO INSTITUTE   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO;

ANKYLOSING SPONDYLITIS; ARTICLE; CALCULATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION MAKING; DISCRIMINANT ANALYSIS; DRUG EFFICACY; EXPERT SYSTEM; HUMAN; INFLAMMATION; INTERNATIONAL COOPERATION; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; PATIENT; PHYSICAL ACTIVITY; PHYSICIAN; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SPINAL PAIN; STATISTICAL ANALYSIS; TREATMENT OUTCOME; VALIDATION PROCESS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS; DELPHI TECHNIQUE; HUMANS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PAIN; SELF ASSESSMENT (PSYCHOLOGY); SENSITIVITY AND SPECIFICITY; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 0037372361     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.62.3.215     Document Type: Article

References (13)

1. van Riel PL, van de Putte LB. DC-ART: what proportion of response constitutes a positive response? J Rheumatol Suppl 1994;41:54-5. discussion 56.
2. Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9.
3. Dougados M, Leclaire P, van der Heijde D, Bloch DA, Bellamy N, Altman RD. Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative. Osteoarthritis Cartilage 2000;8:395-403.
4. van der Heijde D, Calin A, Dougados M, Khan MA, van der Linden S, Bellamy N. Selection of instruments in the core set for DC-ART, SMARD, physical therapy, and clinical record keeping in ankylosing spondylitis. Progress report of the ASAS Working Group. J Rheumatol 1999;26:951-4.
5. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
6. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
7. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
8. Ward MM. Response criteria and criteria far clinically important improvement: separate and equal? Arthritis Rheum 2001;44:1728-9.
9. Dougados M, Gueguen A, Nakache JP, Velicitat P, Veys EM, Zeidler H, et al. Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology (Oxford) 1999;38:235-44.
10. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
11. Jones J, Hunter D. Consensus methods for medical and health services research. BMJ 1995;311:376-80.
12. Kirwan JR, Chaput de Saintonge DM, Joyce CR, Currey HL. Clinical judgment in rheumatoid arthritis. II. Judging 'current disease activity' in clinical practice. Ann Rheum Dis 1983;42:648-51.
13. Scott Lennox JA, McLaughlin Miley C, Lennox RD, Bohlig AM, Cutler BL, Yan C, et al. Stratification of flare intensity identifies placebo responders in a treatment efficacy trial of patients with osteoarthritis. Arthritis Rheum 2001;44:1599-607.